Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short-term Investments: 2015-2022

Historic Short-term Investments for Cartesian Therapeutics (RNAC) over the last 5 years, with Dec 2022 value amounting to $28.2 million.

  • Cartesian Therapeutics' Short-term Investments rose 101.20% to $28.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $28.2 million, marking a year-over-year increase of 101.20%. This contributed to the annual value of $28.2 million for FY2022, which is 101.20% up from last year.
  • According to the latest figures from Q4 2022, Cartesian Therapeutics' Short-term Investments is $28.2 million, which was down 16.18% from $33.6 million recorded in Q3 2022.
  • In the past 5 years, Cartesian Therapeutics' Short-term Investments ranged from a high of $33.6 million in Q3 2022 and a low of $278,000 during Q2 2020.
  • Over the past 3 years, Cartesian Therapeutics' median Short-term Investments value was $18.2 million (recorded in 2021), while the average stood at $15.5 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Short-term Investments tumbled by 98.28% in 2020 and then skyrocketed by 8,673.02% in 2021.
  • Over the past 5 years, Cartesian Therapeutics' Short-term Investments (Quarterly) stood at $6.0 million in 2018, then skyrocketed by 91.95% to $279,000 in 2019, then tumbled by 97.58% to $278,000 in 2020, then skyrocketed by 8,673.02% to $14.0 million in 2021, then skyrocketed by 101.20% to $28.2 million in 2022.
  • Its Short-term Investments stands at $28.2 million for Q4 2022, versus $33.6 million for Q3 2022 and $4.0 million for Q2 2022.